ProPhase Labs (NASDAQ:PRPH) Given News Impact Rating of 0.20
Media headlines about ProPhase Labs (NASDAQ:PRPH) have trended somewhat positive on Tuesday, Accern Sentiment reports. Accern rates the sentiment of news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. ProPhase Labs earned a media sentiment score of 0.20 on Accern’s scale. Accern also gave news headlines about the company an impact score of 47.1332193126777 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the news headlines that may have effected Accern Sentiment Analysis’s scoring:
- ProPhase Labs, Inc. (Formerly Known as Quigley Corporation) (biospace.com)
- BRIEF-Prophase Labs Inc qtrly sales $1.9 million (PRPH) (markets.businessinsider.com)
- ProPhase Labs, Inc. (PRPH) Releases Quarterly Earnings Results (americanbankingnews.com)
- ProPhase Labs Reports Financial Results for the Three Months and Six Months Ended June 30, 2017 (finance.yahoo.com)
ProPhase Labs (PRPH) opened at 2.06 on Tuesday. ProPhase Labs has a 1-year low of $1.70 and a 1-year high of $2.45. The stock’s 50 day moving average is $2.06 and its 200-day moving average is $2.03. The firm has a market capitalization of $35.34 million, a P/E ratio of 0.82 and a beta of 0.07.
ProPhase Labs (NASDAQ:PRPH) last posted its earnings results on Friday, August 11th. The company reported ($0.09) EPS for the quarter. The business had revenue of $1.91 million for the quarter. ProPhase Labs had a return on equity of 88.57% and a net margin of 262.61%.
WARNING: “ProPhase Labs (NASDAQ:PRPH) Given News Impact Rating of 0.20” was first posted by Watch List News and is owned by of Watch List News. If you are viewing this report on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this report can be read at https://www.watchlistnews.com/prophase-labs-nasdaqprph-given-news-impact-rating-of-0-20/1488348.html.
About ProPhase Labs
ProPhase Labs, Inc manufactures, markets and distributes a range of homeopathic and healthcare products. The Company is engaged in the research and development of over-the-counter (OTC) drugs and natural base health products, including supplements, personal care and cosmeceutical products. The Company’s products include TK Supplements and ORXx Complete.
Receive News & Ratings for ProPhase Labs Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.